anti-arrhythmia agents

Phase 3Small molecule

NNational Heart, Lung, and Blood Institute (NHLBI)

anti-arrhythmia agents is one of 21 small molecule programs targeting Tachycardia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TachycardiaActive, not recruiting

TachycardiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

27 competitors in Tachycardia

#DrugCompanyPhaseTrials

Epsom Salt

FFresenius Kabi Oncology Ltd.

Approved

1 2

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

1 3

Inderal

WWyeth-Lederle Vaccines

Approved

1 4

Corlanor

Amgen

Phase 3

4 5

Rapiblyk

AAultman Health Foundation

Approved

1 6

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 7

Lodosyn

LLaTonya J. Hickson

Phase 3

1 8

Beta Blocker

WWeill Medical College of Cornell University

Phase 3

1 9

Mestinon

UUnited BioPharma

Phase 2

1 10

Iron

WWatson Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tachycardia1 trial

Multicenter Unsustained Tachycardia Trial (MUSTT)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000480

Drug Therapy1 trial

A Comparison of the Drug Therapy Versus Re-Ablation

Completed·MMeshalkin Research Institute of Pathology of Circulation·Phase 2·NCT01709682·154 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for anti-arrhythmia agents. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — anti-arrhythmia agents compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for anti-arrhythmia agents. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Heart, Lung, and Blood Institute (NHLBI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNational Heart, Lung, and Blood Institute (NHLBI)

anti-arrhythmia agents

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tachycardia1 trial

Drug Therapy1 trial

References

Drug Info

Quick Facts

Related News